Literature DB >> 32503875

Oral epithelial IL-22/STAT3 signaling licenses IL-17-mediated immunity to oral mucosal candidiasis.

Felix E Y Aggor1, Timothy J Break2, Giraldina Trevejo-Nuñez3, Natasha Whibley1, Bianca M Coleman1, Rachel D Bailey1, Daniel H Kaplan4,5, Julian R Naglik6, Wei Shan7, Amol C Shetty8, Carrie McCracken8, Scott K Durum7, Partha S Biswas1, Vincent M Bruno8, Jay K Kolls9, Michail S Lionakis2, Sarah L Gaffen10.   

Abstract

Oropharyngeal candidiasis (OPC; thrush) is an opportunistic infection caused by the commensal fungus Candida albicans Interleukin-17 (IL-17) and IL-22 are cytokines produced by type 17 lymphocytes. Both cytokines mediate antifungal immunity yet activate quite distinct downstream signaling pathways. While much is now understood about how IL-17 promotes immunity in OPC, the activities of IL-22 are far less well delineated. We show that, despite having similar requirements for induction from type 17 cells, IL-22 and IL-17 function nonredundantly during OPC. We find that the IL-22 and IL-17 receptors are required in anatomically distinct locations within the oral mucosa; loss of IL-22RA1 or signal transducer and activator of transcription 3 (STAT3) in the oral basal epithelial layer (BEL) causes susceptibility to OPC, whereas IL-17RA is needed in the suprabasal epithelial layer (SEL). Transcriptional profiling of the tongue linked IL-22/STAT3 not only to oral epithelial cell proliferation and survival but also, unexpectedly, to driving an IL-17-specific gene signature. We show that IL-22 mediates regenerative signals on the BEL that replenish the IL-17RA-expressing SEL, thereby restoring the ability of the oral epithelium to respond to IL-17 and thus to mediate antifungal events. Consequently, IL-22 signaling in BEL "licenses" IL-17 signaling in the oral mucosa, revealing spatially distinct yet cooperative activities of IL-22 and IL-17 in oral candidiasis.
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32503875      PMCID: PMC7340112          DOI: 10.1126/sciimmunol.aba0570

Source DB:  PubMed          Journal:  Sci Immunol        ISSN: 2470-9468


  111 in total

Review 1.  IL-17-Mediated Immunity to the Opportunistic Fungal Pathogen Candida albicans.

Authors:  Heather R Conti; Sarah L Gaffen
Journal:  J Immunol       Date:  2015-08-01       Impact factor: 5.422

2.  Epithelial cell-derived S100 calcium-binding proteins as key mediators in the hallmark acute neutrophil response during Candida vaginitis.

Authors:  Junko Yano; Elizabeth Lilly; Melissa Barousse; Paul L Fidel
Journal:  Infect Immun       Date:  2010-09-07       Impact factor: 3.441

Review 3.  Interleukin-26: An Emerging Player in Host Defense and Inflammation.

Authors:  Sara Tengvall; Karlhans Fru Che; Anders Lindén
Journal:  J Innate Immun       Date:  2015-07-21       Impact factor: 7.349

Review 4.  Autoimmune polyendocrine syndromes: clues to type 1 diabetes pathogenesis.

Authors:  Eystein S Husebye; Mark S Anderson
Journal:  Immunity       Date:  2010-04-23       Impact factor: 31.745

5.  Pathogenic NLRP3 Inflammasome Activity during Candida Infection Is Negatively Regulated by IL-22 via Activation of NLRC4 and IL-1Ra.

Authors:  Monica Borghi; Antonella De Luca; Matteo Puccetti; Martin Jaeger; Antonella Mencacci; Vasilis Oikonomou; Marilena Pariano; Cecilia Garlanda; Silvia Moretti; Andrea Bartoli; Jack Sobel; Frank L van de Veerdonk; Charles A Dinarello; Mihai G Netea; Luigina Romani
Journal:  Cell Host Microbe       Date:  2015-08-12       Impact factor: 21.023

6.  A novel Th cell epitope of Candida albicans mediates protection from fungal infection.

Authors:  Eva Bär; André Gladiator; Sonia Bastidas; Bernd Roschitzki; Hans Acha-Orbea; Annette Oxenius; Salomé LeibundGut-Landmann
Journal:  J Immunol       Date:  2012-04-23       Impact factor: 5.422

7.  Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.

Authors:  Emma Guttman-Yassky; Patrick M Brunner; Avidan U Neumann; Saakshi Khattri; Ana B Pavel; Kunal Malik; Giselle K Singer; Danielle Baum; Patricia Gilleaudeau; Mary Sullivan-Whalen; Sharon Rose; Shelbi Jim On; Xuan Li; Judilyn Fuentes-Duculan; Yeriel Estrada; Sandra Garcet; Claudia Traidl-Hoffmann; James G Krueger; Mark G Lebwohl
Journal:  J Am Acad Dermatol       Date:  2018-01-17       Impact factor: 11.527

8.  Defective IL-17- and IL-22-dependent mucosal host response to Candida albicans determines susceptibility to oral candidiasis in mice expressing the HIV-1 transgene.

Authors:  Mathieu Goupil; Vincent Cousineau-Côté; Francine Aumont; Serge Sénéchal; Louis Gaboury; Zaher Hanna; Paul Jolicoeur; Louis de Repentigny
Journal:  BMC Immunol       Date:  2014-10-26       Impact factor: 3.615

9.  Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis.

Authors:  Heather R Conti; Fang Shen; Namrata Nayyar; Eileen Stocum; Jianing N Sun; Matthew J Lindemann; Allen W Ho; Justine Hoda Hai; Jeffrey J Yu; Ji Won Jung; Scott G Filler; Patricia Masso-Welch; Mira Edgerton; Sarah L Gaffen
Journal:  J Exp Med       Date:  2009-02-09       Impact factor: 14.307

10.  Oral-resident natural Th17 cells and γδ T cells control opportunistic Candida albicans infections.

Authors:  Heather R Conti; Alanna C Peterson; Lucas Brane; Anna R Huppler; Nydiaris Hernández-Santos; Natasha Whibley; Abhishek V Garg; Michelle R Simpson-Abelson; Gregory A Gibson; Anna J Mamo; Lisa C Osborne; Shrinivas Bishu; Nico Ghilardi; Ulrich Siebenlist; Simon C Watkins; David Artis; Mandy J McGeachy; Sarah L Gaffen
Journal:  J Exp Med       Date:  2014-09-08       Impact factor: 14.307

View more
  23 in total

1.  An IL-17F.S65L Knock-In Mouse Reveals Similarities and Differences in IL-17F Function in Oral Candidiasis: A New Tool to Understand IL-17F.

Authors:  Chunsheng Zhou; Leticia Monin; Rachael Gordon; Felix E Y Aggor; Rami Bechara; Tara N Edwards; Daniel H Kaplan; Sebastien Gingras; Sarah L Gaffen
Journal:  J Immunol       Date:  2020-06-29       Impact factor: 5.422

2.  Mucosal fungi promote gut barrier function and social behavior via Type 17 immunity.

Authors:  Irina Leonardi; Iris H Gao; Woan-Yu Lin; Megan Allen; Xin V Li; William D Fiers; Meghan Bialt De Celie; Gregory G Putzel; Rhonda K Yantiss; Melanie Johncilla; Dilek Colak; Iliyan D Iliev
Journal:  Cell       Date:  2022-02-16       Impact factor: 41.582

Review 3.  The role of Th17 cells: explanation of relationship between periodontitis and COPD?

Authors:  Jiaohong Liu; Yuanting Ouyang; Zhiyi Zhang; Siyi Wen; Yixing Pi; Ding Chen; Zhikang Su; Zitian Liang; Lvhua Guo; Yan Wang
Journal:  Inflamm Res       Date:  2022-07-04       Impact factor: 6.986

Review 4.  Infections in the monogenic autoimmune syndrome APECED.

Authors:  Vasileios Oikonomou; Timothy J Break; Sarah L Gaffen; Niki M Moutsopoulos; Michail S Lionakis
Journal:  Curr Opin Immunol       Date:  2021-08-18       Impact factor: 7.268

5.  A pan-cancer mycobiome analysis reveals fungal involvement in gastrointestinal and lung tumors.

Authors:  Anders B Dohlman; Jared Klug; Marissa Mesko; Iris H Gao; Steven M Lipkin; Xiling Shen; Iliyan D Iliev
Journal:  Cell       Date:  2022-09-29       Impact factor: 66.850

Review 6.  The impact of the Fungus-Host-Microbiota interplay upon Candida albicans infections: current knowledge and new perspectives.

Authors:  Christophe d'Enfert; Ann-Kristin Kaune; Leovigildo-Rey Alaban; Sayoni Chakraborty; Nathaniel Cole; Margot Delavy; Daria Kosmala; Benoît Marsaux; Ricardo Fróis-Martins; Moran Morelli; Diletta Rosati; Marisa Valentine; Zixuan Xie; Yoan Emritloll; Peter A Warn; Frédéric Bequet; Marie-Elisabeth Bougnoux; Stephanie Bornes; Mark S Gresnigt; Bernhard Hube; Ilse D Jacobsen; Mélanie Legrand; Salomé Leibundgut-Landmann; Chaysavanh Manichanh; Carol A Munro; Mihai G Netea; Karla Queiroz; Karine Roget; Vincent Thomas; Claudia Thoral; Pieter Van den Abbeele; Alan W Walker; Alistair J P Brown
Journal:  FEMS Microbiol Rev       Date:  2021-05-05       Impact factor: 16.408

7.  Aberrant type 1 immunity drives susceptibility to mucosal fungal infections.

Authors:  Timothy J Break; Vasileios Oikonomou; Nicolas Dutzan; Jigar V Desai; Marc Swidergall; Tilo Freiwald; Daniel Chauss; Oliver J Harrison; Julie Alejo; Drake W Williams; Stefania Pittaluga; Chyi-Chia R Lee; Nicolas Bouladoux; Muthulekha Swamydas; Kevin W Hoffman; Teresa Greenwell-Wild; Vincent M Bruno; Lindsey B Rosen; Wint Lwin; Andy Renteria; Sergio M Pontejo; John P Shannon; Ian A Myles; Peter Olbrich; Elise M N Ferré; Monica Schmitt; Daniel Martin; Daniel L Barber; Norma V Solis; Luigi D Notarangelo; David V Serreze; Mitsuru Matsumoto; Heather D Hickman; Philip M Murphy; Mark S Anderson; Jean K Lim; Steven M Holland; Scott G Filler; Behdad Afzali; Yasmine Belkaid; Niki M Moutsopoulos; Michail S Lionakis
Journal:  Science       Date:  2021-01-15       Impact factor: 47.728

8.  Candidalysin triggers epithelial cellular stresses that induce necrotic death.

Authors:  Mariana Blagojevic; Giorgio Camilli; Michelle Maxson; Bernhard Hube; David L Moyes; Jonathan P Richardson; Julian R Naglik
Journal:  Cell Microbiol       Date:  2021-06-16       Impact factor: 4.115

Review 9.  Crosstalk between the oral microbiota, mucosal immunity, and the epithelial barrier regulates oral mucosal disease pathogenesis.

Authors:  Dongjia Lin; Lisa Yang; Liling Wen; Huanzi Lu; Qianming Chen; Zhi Wang
Journal:  Mucosal Immunol       Date:  2021-05-26       Impact factor: 7.313

10.  Tissue Damage in Radiation-Induced Oral Mucositis Is Mitigated by IL-17 Receptor Signaling.

Authors:  Jessica Saul-McBeth; John Dillon; Aaron Lee; Dylan Launder; Jacqueline M Kratch; Eanas Abutaha; Alexandria A Williamson; Allen G Schroering; Grace Michalski; Priosmita Biswas; Samuel R Conti; Amol C Shetty; Carrie McCracken; Vincent M Bruno; E Ishmael Parsai; Heather R Conti
Journal:  Front Immunol       Date:  2021-06-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.